BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides-Reference-Cited by-同舟云学术

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Published:2017-06-15 Issue:11 Volume:57 Page:1460-1471
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Sakamoto Kei¹,Matsuki Shunji¹,Matsuguma Kyoko¹,Yoshihara Tatsuya¹,Uchida Naoki²,Azuma Fumihiko³,Russell Muir⁴,Hughes Glen⁴,Haeberlein Samantha Budd⁵,Alexander Robert C.⁵,Eketjäll Susanna⁶,Kugler Alan R.⁵

Affiliation:

1. Souseikai Fukuoka Mirai Hospital Clinical Research Center; Fukuoka Japan

2. Clinical Pharmacology; Pharmacology; Showa University School of Medicine; Tokyo Japan

3. Research & Development; AstraZeneca KK; Osaka Japan

4. AstraZeneca; Protein Biomarkers; Personalised Healthcare and Biomarkers; Innovative Medicines and Early Development Biotech Unit, AstraZeneca; Alderley Park UK

5. Neuroscience; Innovative Medicines and Early Development Biotech Unit; AstraZeneca; Waltham MA USA

6. Cardiovascular and Metabolic Diseases; Innovative Medicines and Early Development Biotech Unit; AstraZeneca; Huddinge Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. The molecular pathology of Alzheimer's disease;Selkoe;Neuron,1991

2. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease;Vassar;Alzheimer's Res Ther,2014

3. WHO Dementia 2015 http://www.who.int/mediacentre/factsheets/fs362/en

4. Alzheimer's and Dementia in Japan http://www.alz.org/jp/dementia-alzheimers-japan.asp 2016

5. Casey DA Antimisiaris D O'Brien J Drugs for Alzheimer's disease: are they effective? P&T 2010 35 4 208 211

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coptisine reverses Alzheimer’s disease by targeting cholinergic and amyloidogenic pathways;Medical Hypotheses;2024-08

2. The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer’s Disease: Role for Natural Antioxidants and Immunotherapeutics;Antioxidants;2024-07-18

3. Navigating the Alzheimer's Treatment Landscape: UnravelingAmyloid-beta Complexities and Pioneering Precision MedicineApproaches;Current Topics in Medicinal Chemistry;2024-07

4. Oxygen metabolism abnormality and Alzheimer's disease: An update;Redox Biology;2023-12

5. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future;Signal Transduction and Targeted Therapy;2023-06-30